Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis

被引：55
|
作者：
Mildiner, Sorcha [1 ]
Malnick, Stephen [1 ]
机构：
[1] Kaplan Med Ctr, Rehovot, Israel
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 17期
关键词：
D O I：
10.1056/NEJMc1702076
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1692 / 1693
页数：2
相关论文
共 50 条
  • [31] Beyond ocrelizumab in primary progressive multiple sclerosis
    Williams, Thomas
    Chataway, Jeremy
    NATURE REVIEWS NEUROLOGY, 2022, 18 (11) : 641 - 642
  • [32] Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
    Martins, Paulo
    Vandewalle, Bjorn
    Felix, Jorge
    Capela, Carlos M.
    Cerqueira, Joao J.
    Salgado, Antonio, V
    Ferreira, Diana G.
    Monteiro, Isabel
    PHARMACOECONOMICS-OPEN, 2023, 7 (02) : 229 - 241
  • [33] Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
    Paulo Martins
    Björn Vandewalle
    Jorge Félix
    Carlos M. Capela
    João J. Cerqueira
    António V. Salgado
    Diana G. Ferreira
    Isabel Monteiro
    PharmacoEconomics - Open, 2023, 7 : 229 - 241
  • [34] Ocrelizumab: A New B-cell Therapy for Relapsing Remitting and Primary Progressive Multiple Sclerosis
    Stahnke, Amanda M.
    Holt, Kathryn M.
    ANNALS OF PHARMACOTHERAPY, 2018, 52 (05) : 473 - 483
  • [35] Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
    Montalban, X.
    Hauser, S. L.
    Kappos, L.
    Arnold, D. L.
    Bar-Or, A.
    Comi, G.
    de Seze, J.
    Giovannoni, G.
    Hartung, H. -P.
    Hemmer, B.
    Lublin, F.
    Rammohan, K. W.
    Selmaj, K.
    Traboulsee, A.
    Sauter, A.
    Masterman, D.
    Fontoura, P.
    Belachew, S.
    Garren, H.
    Mairon, N.
    Chin, P.
    Wolinsky, J. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 209 - 220
  • [36] Comparison of cognitive functions in relapsing and progressive multiple sclerosis patients on ocrelizumab treatment
    Ozakbas, S.
    Ozcelik, S.
    Kaya, E.
    Ozdogar, T.
    Sagici, O.
    Baba, C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (2_SUPPL) : 9 - 9
  • [37] Safety results for administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis
    Vollmer, T.
    Alvarez, E.
    Nair, K. V.
    Cohen, J.
    Boster, A.
    Katz, J.
    Pardo, G.
    Pei, J.
    Raut, P.
    Merchant, S.
    Bobbala, A.
    Pradhan, A.
    Moss, B.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 778 - 779
  • [38] Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis
    Vollmer, Timothy L.
    Cohen, Jeffrey A.
    Alvarez, Enrique
    Nair, Kavita, V
    Boster, Aaron
    Katz, Joshua
    Pardo, Gabriel
    Pei, Jinglan
    Raut, Pranil
    Merchant, Sharmin
    MacLean, Elizabeth
    Pradhan, Ashish
    Moss, Brandon
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [39] Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis
    Bar-or, A.
    Thanei, G. -A.
    Harp, C.
    Cross, A.
    Hauser, S.
    Jia, X.
    Kuhle, J.
    Leppert, D.
    Model, F.
    Fiore, D.
    Koendgen, H.
    Hendricks, R.
    Fischer, S.
    Manfrini, M.
    Herman, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 197 - 197
  • [40] Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
    Gibiansky, Ekaterina
    Petry, Claire
    Mercier, Francois
    Gunther, Andreas
    Herman, Ann
    Kappos, Ludwig
    Hauser, Stephen
    Yamamoto, Yumi
    Wang, Qing
    Model, Fabian
    Kletzl, Heidemarie
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (06) : 2511 - 2520
12345